Pfizer (PFE) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Pfizer (PFE) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 -71.88%
Jun 29, 2025 -51.09%
Sep 29, 2024 -31.95%
Dec 31, 2023 -14.91%
Oct 1, 2023 1.76%
Apr 2, 2023 24.57%
Jul 3, 2022 76.23%
Jul 4, 2021 -198.76%
Sep 27, 2020 133.89%
Jun 28, 2020 289.20%
Mar 29, 2020 181.32%
Dec 31, 2019 223.86%
Sep 29, 2019 27.23%
Dec 31, 2018 164.88%
Sep 30, 2018 0.00%
Apr 1, 2018 -14.95%
Dec 31, 2017 -78.19%
Dec 31, 2016 -61.48%
Jul 3, 2016 -59.95%
Dec 31, 2015 26.77%